Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
06:39am, Wednesday, 18'th Sep 2024
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
08:00am, Tuesday, 20'th Aug 2024
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chi
Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript
04:25pm, Friday, 09'th Aug 2024
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve G
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
07:00am, Friday, 09'th Aug 2024
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financia
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
07:00am, Friday, 26'th Jul 2024
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
10:21am, Monday, 15'th Jul 2024
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
08:41am, Monday, 15'th Jul 2024
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
08:00am, Wednesday, 10'th Jul 2024
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET o
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
12:15pm, Monday, 17'th Jun 2024
Shares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being among the top pharma gainers in the first week of June.
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Co
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Offi
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
05:00pm, Thursday, 23'rd May 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical deve
Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript
12:13pm, Monday, 13'th May 2024
Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2024 Earnings Call Transcript May 13, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chie
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
07:00am, Monday, 13'th May 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
09:56am, Thursday, 09'th May 2024
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
